Last reviewed · How we verify

NCT06982417

InsightRP2 Registry

Recruiting now Last updated 21 May 2025
What this trial tests

trial in RP2-associated Retinitis Pigmentosa in 200 participants. Currently enrolling.

Timeline
1 May 2025
Primary endpoint
1 May 2045
1 May 2045

Quick facts

Lead sponsorUniversity of Göttingen
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment200
Start date1 May 2025
Primary completion1 May 2045
Estimated completion1 May 2045
Sites1 location across Germany

Conditions studied

Sponsor

University of Göttingen

Who can join

Eligibility, any sex, with RP2-associated Retinitis Pigmentosa or X-Linked Retinitis Pigmentosa (XLRP). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

InsightRP2 is a secure online patient registry specific to RP2-associated retinitis pigmentosa (RP). It is our goal to further the scientific understanding of this rare disease and to support research in to a gene therapy for RP2-associated RP. We collect medical, genetic and imaging data from people affected by RP2-associated RP and will coduct a natural history study as well as image analysis studies.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other University of Göttingen trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06982417.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing